Fatty acid-binding protein 4 (FABP4; also known as aP2) is an active adipokine that regulates hepatic glucose production and systemic glucose homeostasis and has been implicated in the pathogenesis of diabetes. However, therapeutically targeting FABP4 has so far been challenging. Now, Burak et al. identify a FABP4-specific monoclonal antibody — CA33 — that improved glucose metabolism, decreased fat mass, increased systemic insulin sensitivity and reduced liver steatosis in genetic and dietary mouse obesity models.
References
Burak, M. F. et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid–binding protein aP2 to treat type 2 diabetes. Sci. Transl Med. 7, 319ra205 (2015)
Rights and permissions
About this article
Cite this article
Crunkhorn, S. Targeting aP2 reverses diabetes. Nat Rev Drug Discov 15, 86 (2016). https://doi.org/10.1038/nrd.2016.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.4